| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IC50: 12 nM (FAK), <0.5 nM (D835Y)[2].
FLT3 mutants (especially D835Y) and FAK (focal adhesion kinase). FLT3-IN-17 inhibits FLT3 mutants with an IC50 <0.5 nM for the D835Y variant and inhibits FAK with an IC50 of 12 nM. It also inhibits the activity of CYP enzymes. |
|---|---|
| ln Vitro |
In HCT-116, MDA-MB-231, and A375 cells, FLT3-IN-17 (compound 25, 72 h) suppresses cell growth[1]. With inhibition rates more than 55%, FLT3-IN-17 (10 μM) inhibits cytochrome P450s (CYPs). FLT3-IN-17 suppresses the activity of FLT3 mutants (IC50s: 1.6-183 nM for Ba/F3, <0.5 nM for D835Y)[1].
FLT3-IN-17 inhibits FLT3 mutants, with an IC50 <0.5 nM for the D835Y resistance mutation, indicating it can overcome resistance to first-generation FLT3 inhibitors. It is also a FAK inhibitor with an IC50 of 12 nM, and it inhibits the activity of cytochrome P450 (CYP) enzymes. These multi-target activities make it useful for cancer research. |
| ln Vivo |
No specific in vivo activity data are reported for FLT3-IN-17. As a potent FLT3 mutant inhibitor and FAK inhibitor, it is expected to have anti-tumor activity in AML xenograft models driven by FLT3 mutations and in solid tumor models where FAK plays a role in metastasis. It can be used in cancer research.
|
| Enzyme Assay |
Cell-free FLT3 mutant kinase assays (D835Y) and FAK kinase assays are performed using recombinant enzymes. The compound is incubated with the enzyme and a peptide substrate in the presence of ATP for 30-60 minutes. Kinase activity is measured using a luminescence-based ADP detection kit. IC50 values (<0.5 nM for D835Y, 12 nM for FAK) are calculated. CYP inhibition assays are performed using standard CYP probe substrates.
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: HCT-116 , MDA-MB-231, A375 cells Tested Concentrations: 0-1 μM approximately Incubation Duration: 72 h Experimental Results: Inhibited cell growth with IC50 values of 0.25, 0.46, 0.49 μM respectively. FLT3-mutant human AML cell lines (e.g., MV4-11) are seeded in 96-well plates and treated with increasing concentrations of FLT3-IN-17 for 72 hours. Cell viability is assessed by MTT assay. FLT3 and FAK phosphorylation are measured by Western blotting. Apoptosis is measured by Annexin V/PI staining. For FAK activity, cancer cell lines with high FAK expression can be used. |
| Animal Protocol |
For in vivo studies, FLT3-IN-17 would be administered orally to mice bearing FLT3-mutant AML xenografts. Dosing schedules are not specified. Tumor volumes are measured with calipers. At study termination, tumors are excised for analysis of FLT3 and FAK phosphorylation and downstream signaling. No published studies are available.
|
| ADME/Pharmacokinetics |
No specific PK data are reported for FLT3-IN-17. The molecular weight is 478.33 (C21H19BrF3N5O). CAS 2758999-62-9. It is soluble in DMSO (10-50 mg/mL). For in vivo studies, it would typically be formulated in 0.5% methylcellulose. PK parameters have not been characterized. The compound's CYP inhibition activity may affect its PK profile.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for FLT3-IN-17. As a FLT3 and FAK inhibitor with CYP inhibition activity, there is a potential risk of drug-drug interactions due to CYP inhibition. Comprehensive toxicological assessments have not been published. The compound is for research use only and is not an FDA-approved drug.
|
| References | |
| Additional Infomation |
Other information: FLT3-IN-17 (CAS 2758999-62-9) is a research compound and not FDA-approved. It is a potent inhibitor of FLT3 mutants (IC50 <0.5 nM for D835Y) and FAK (IC50 = 12 nM), and also inhibits CYP enzymes. It is a valuable multi-target tool for cancer research. For research use only.
|
| Molecular Formula |
C23H24N6O2S2
|
|---|---|
| Molecular Weight |
480.605661392212
|
| Exact Mass |
480.14
|
| CAS # |
2758999-62-9
|
| PubChem CID |
164627080
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
736
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CS(NC1=CC=CC(C2C3C(SC=2)=CN=C(NC2=CC=C(N4CCNCC4)C=C2)N=3)=C1)(=O)=O
|
| InChi Key |
MGKRFMQUFDKUBA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H24N6O2S2/c1-33(30,31)28-18-4-2-3-16(13-18)20-15-32-21-14-25-23(27-22(20)21)26-17-5-7-19(8-6-17)29-11-9-24-10-12-29/h2-8,13-15,24,28H,9-12H2,1H3,(H,25,26,27)
|
| Chemical Name |
N-[3-[2-(4-piperazin-1-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 7.5 mg/mL (15.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0807 mL | 10.4034 mL | 20.8069 mL | |
| 5 mM | 0.4161 mL | 2.0807 mL | 4.1614 mL | |
| 10 mM | 0.2081 mL | 1.0403 mL | 2.0807 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
